De novo hepatocellular carcinoma in living donor liver grafts: A Japanese multicenter experience.
Ryoichi GotoYukiko Kosai-FujimotoShintaro YagiTsuyoshi KobayashiNobuhisa AkamatsuTsuyoshi ShimamuraSatoru ImuraSatoshi OgisoShugo MizunoMitsuhisa TakatsukiTakasuke FukuharaTatsuya KantoSusumu EguchiKatsuhiko YanagaYasuhiro OguraTakumi FukumotoMitsuo ShimadaKiyoshi HasegawaHideki OhdanShinji UemotoYuji SoejimaToru IkegamiTomoharu YoshizumiAkinobu TaketomiYoshihiko MaeharaPublished in: Hepatology research : the official journal of the Japan Society of Hepatology (2020)
Analysis of the database from major liver transplantation institutes in Japan revealed that de novo HCCs determined by microsatellite analysis were rarely detected, but the majority were successfully treated. LDLT recipients with higher risks of de novo HCC, including those with hepatitis B core antibody-positive grafts, should be carefully followed by surveillance of the liver graft.